Chronic Kidney Disease (Chronic Renal Failure) Market Scenario, Epidemiology Insights and Forecast 2030

Chronic kidney disease (CKD) is a syndrome where there are persistent alterations in kidney structure, function, or both with implications on the health of the individual. Examples of structural abnormalities include cysts, tumors, malformations and atrophy, which are evident on imaging. By contrast, kidney dysfunction can manifest as hypertension, edema, changes in output or quality of urine and growth delay in children, these changes are most often recognized by increased serum levels of creatinine, cystatin C, or blood urea nitrogen. The most common pathological manifestation of CKD, regardless of the initiating insult or disease, is some form of renal fibrosis. 

 

 

DelveInsight’s ‘Chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast-2030" report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of CKD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chronic kidney disease (CKD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017–2030

Chronic kidney disease (CKD) Treatment Algorithm

Several aspects need to be considered when managing patients with CKD, including controlling further nephron injury, normalizing single-nephron hyperfiltration, controlling CKD-related complications and preparing the patient for kidney replacement therapy. At the core of these is the principle of ‘the earlier, the better’, which is the effort to reduce the progression to ESRD and optimize renal outcomes. 

Chronic Kidney Disease Diagnosis

The clinical presentation of CKD depends on the underlying disorder and the severity of renal impairment. Patients with early stages of CKD (G1–G2) are usually asymptomatic, but from CKD G3 onwards, patients may experience weakness related to anemia and polyuria. CKD can be detected during a routine periodic health assessment, during the evaluation of individuals at risk of CKD, as a consequence of the incidental finding of abnormal laboratory values in connection with another acute or chronic illness, during an investigation of symptoms and/or signs relating to the kidneys or urinary tract (such as hematuria) or after the discovery of abnormal laboratory values in a population-based screening program.

Chronic Kidney Disease Treatment 

It covers the details of conventional and current medical therapies available in the Chronic Kidney Disease market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan. 

The DelveInsight Chronic Kidney Disease market report gives a thorough understanding of CKD by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides CKD treatment algorithms and treatment guidelines in the US, Europe, and Japan. 

Request for sample pages: https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market

Chronic kidney disease Epidemiology

The Chronic kidney disease (CKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD) scenario of Chronic kidney disease (CKD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030. According to DelveInsight, the total number of prevalent cases of Chronic kidney disease (CKD) in 7 MM was found to be 122,704,658 in the year 2017.

Chronic kidney disease Drug Chapters

This segment of the Chronic Kidney Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details and the latest news and press releases.

The chronic kidney disease (CKD) drugs market is categorized on the basis of drug class such as Erythropoietin stimulating agents (ESA), Angiotensin-converting-enzyme inhibitors and Angiotensin receptor blockers (ACE-I and ARBs), Antidiabetics, Secondary Hyperparathyroidism Treatment (SHPT), and Urate Lowering Therapies.

Chronic kidney disease Marketed Drugs

Aranesp (darbepoetin alfa): Amgen 

Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating protein that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. It is a synthetic form of erythropoietin that stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy and works similar like endogenous erythropoietin

Products detail in the report…

Chronic kidney disease Emerging Drugs

Daprodustat: GlaxoSmithKline

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The product is being developed by GlaxoSmithKline and company has filed the application to the Japan authorities for the treatment of Anemia Associated with Chronic Kidney Disease.

Products detail in the report…

Download report: https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market

Chronic Kidney Disease Market Outlook

The Chronic kidney disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of chronic kidney disease in 7MM is expected to undergo a major positive shift during the course of the study period (2017–2030). Among the 7MM, the United States accounts for the largest market size of CKD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. As per DelveInsight's analysis the market size for CKD is expected to increase with a CAGR of 5.9% during the forecast period for 7MM.

Key Findings

This section includes a glimpse of the Chronic Kidney Disease market in 7MM.

The United States Market Outlook

This section provides the total Chronic Kidney Disease market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Chronic Kidney Disease market size and market size by therapies in Germany, France, Italy, Spain and the United Kingdom is provided in this section.

Japan Market Outlook 

The total Chronic Kidney Disease market size and market size by therapies in Japan is also mentioned. 

Request for sample pages: https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market

Browse through our repository of reports: https://www.delveinsight.com/report-store.php